Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success

Tedizolid has activity against Gram-positive pathogens as well as Mycobacterium spp and Nocardia spp. Real-world evidence supporting long-term tolerability and clinical success of tedizolid is lacking. Prolonged tedizolid therapy (median, 188 days; interquartile range, 62–493 days) appeared to be we...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrisette, Taylor, Molina, Kyle C, Da Silva, Beatriz, Mueller, Scott W, Damioli, Laura, Krsak, Martin, Miller, Matthew A, Fish, Douglas N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126493/
https://www.ncbi.nlm.nih.gov/pubmed/35615295
http://dx.doi.org/10.1093/ofid/ofac028
Descripción
Sumario:Tedizolid has activity against Gram-positive pathogens as well as Mycobacterium spp and Nocardia spp. Real-world evidence supporting long-term tolerability and clinical success of tedizolid is lacking. Prolonged tedizolid therapy (median, 188 days; interquartile range, 62–493 days) appeared to be well tolerated in 37 patients (8.1% experienced adverse effect leading to discontinuation). Clinical success was 81.3% in those evaluated.

Ejemplares similares